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1. INTRODUCTION 
The blood-brain barrier (BBB) is the major obstacle to prevent potential 
neuropharmaceuticals, especially new biopharmacons, nucleic acids, peptide or protein drugs, 
to reach their targets in the central nervous system (CNS). Therefore, the pharmaceutical 
treatment of most CNS disorders, like stroke, brain tumors and neurodegenerative diseases 
including Alzheimer’s and Parkinson’s diseases, is difficult. Several clinical trials ended with 
failure because of the low penetration of biological drugs across the BBB. The rapidly 
expanding nanotechnology could offer new solutions to solve this problem. Nanoparticles 
(NPs) are colloidal systems, in the range of 1-1000 nm, which consist of macromolecular 
components or metals to carry drugs or bioactive materials (Fig. 1). 
 
Figure 1. Major nanoparticle types applied for drug delivery research 
Drug encapsulation in NPs alone is not enough for their successful delivery to the CNS. 
In order to elevate the permeability of nanocarriers across the BBB speciﬁc targeting is needed. 
Various essential inﬂux transport systems are expressed on the cerebral endothelium playing a 
physiological role in nutrient delivery. These influx transport systems, especially the solute 
carriers (SLCs) of the BBB can potentially be exploited to shuttle nanocarriers to the brain.  
SLC transporters are actively investigated as drug targets and the number of drug 
candidates developed for these carriers and reaching clinical trials increases steadily. However, 
this pathway is not fully utilized for drug delivery and for targeted NPs in particular. Among 
the SLCs, the expression level of glucose transporter GLUT1 (SLC2A1) is the highest at the 
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BBB, but other members of the SLC2A family are also present. Glucose analogs have a 
potential to be eﬃcient and selective targeting ligands for both solid and vesicular nanocarriers 
to cross the BBB. The number and expression level of SLCs transporting amino acids across 
the BBB are also high. Neutral amino acids, like alanine, serine and cysteine, are transported 
by carriers belonging to the sodium-coupled neutral amino acid transporter families 
(SNAT/SLC38A and ASCT/SLC1A), but alanine, a ligand of these transporters has not been 
described as a BBB specific targeting ligand of NPs. 
SLCs also provide the brain with vitamins. The sodium-dependent multivitamin 
transporter (SMVT/SLC5A6) is responsible for the transport of biotin (vitamin B7) across the 
BBB. Biotin has long been used for ligation techniques, imaging and diagnostics based on the 
strong interaction between biotin and avidin. Biotin-avidin technology has a potential to be 
applied for targeted drug therapy of tumors. However, biotin has not yet been tested as a 
potential targeting ligand of NPs to cross brain endothelial cells.  
2. AIMS 
Effective CNS drug targeting with NPs is an unsolved problem. Our main purpose was 
to design nanocarrier systems for elevating the penetration of cargo molecules across the BBB. 
Since SLCs are highly and specifically expressed at the BBB, our hypothesis was that NPs with 
SLC ligands, especially dual ligand combinations will increase the brain endothelial uptake and 
permeability of the cargo across the BBB. Therefore the major aims of our experiments were: 
(I) To verify the gene expression levels of selected SLCs in isolated brain microvessels and 
in vitro BBB models 
(II) To test biotin and glutathione as targeting ligands for polystyrene SNPs on a culture 
BBB model 
(III) To prepare and characterize non-ionic surfactant based vesicular NPs loaded with large 
biomolecule serum albumin as a cargo and targeted with single or dual combination of 
SLC ligands and glutathione 
(IV) To investigate niosomes on cellular viability, uptake and permeability of cargo using a 
BBB culture model 
(V) To reveal the possible mechanisms of the cellular uptake process and the role of the 
brain endothelial surface charge 
(VI) To examine the brain penetration of fluorescent cargo encapsulated in single- and dual 
SLC ligand-targeted niosomes by optical imaging in vivo   
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3. MATERIALS AND METHODS 
3.1. Animals 
Animal studies were performed following the regulations of the 1998. XXVIII. 
Hungarian law and the EU Directive 2010/63/EU (permit numbers: XVI./03835/001/2006, 
XVI./834/2012). For the in vivo experiments ten week old male CD1-Foxn1nu nude mice 
(Charles River Laboratories, Wilmington, MA, USA) were used. For the microvessel and 
primary cell isolations brain tissues were obtained from 3-month-old (microvessels), 3-week-
old (brain endothelial cells and pericytes) or newborn (glial cells) outbred Wistar rats (Harlan 
Laboratories, United Kingdom) of both sexes.  
3.2. Cell cultures 
The following cell cultures were used for our in vitro experiments: human cerebral 
microvascular endothelial cell line (hCMEC/D3), primary rat brain endothelial cells (RBECs) 
in monoculture and in triple co-culture BBB model with pericytes and astrocytes (Fig. 2). 
Figure 2. Schematic drawing of the BBB triple co-culture model and the structure of a brain capillary. TJ: tight 
junction.  
 
3.3. Gene expression study of solute carriers 
RNA was isolated from rat brain microvessels, hCMEC/D3 cells and RBECs from a triple 
co-culture and cDNA was synthetized. The expression of the genes of transporters for glucose 
(GLUT1/SLC2A1, GLUT3/SLC2A3, GLUT5/SLC2A5), for alanine (sodium-coupled neutral 
amino acid transporters SNAT1/SLC38A1, SNAT2/SLC38A2, SNAT3/SLC38A3, 
SNAT5/SLC38A5, ASCT1/SLC1A4, ASCT2/SLC1A5) and for biotin (sodium-dependent 
multivitamin transporter SMVT/SLC5A6) were analyzed by quantitative PCR.  
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3.4. Experiments with targeted solid nanoparticles 
3.4.1. Functionalization and characterization of solid nanoparticles 
Red fluorescent solid nanoparticles (SNPs) made from polystyrene and labeled with 
neutravidin were used for the study. The SNPs were functionalized with biotin (SNP-B) or 
biotinylated-glutathione (SNP-B-GSH) and characterized for particle size and zeta potential 
using dynamic light scattering. The morphology of nanoparticles was visualized by scanning 
electron microscopy. 
3.4.2. Viability measurements and cellular uptake of solid nanoparticles 
The viability and metabolic activity of hCMEC/D3 after treatment with SNPs was 
verified with MTT-test. To measure the cellular uptake of SNPs hCMEC/D3 cells were seeded 
to 24-well plates. The confluent monolayers were incubated with SNP, SNP-B and SNP-B-
GSH at 150 µg/mL concentration for 4 or 8 h at 37 ºC. After incubation the cells were washed 
with ice cold phosphate buffer (PBS) and lysed in Triton X-100 detergent. The fluorescence 
intensity of cell lysates was measured with a spectrofluorometer at 488 nm excitation and 605 
nm emission wavelengths. The cellular uptake of the fluorescent SNPs was visualized with a 
confocal laser scanning microscope. 
3.4.3. Permeability measurement of solid nanoparticles 
For permeability studies the hCMEC/D3 cells were seeded onto collagen coated 12-well 
tissue culture inserts and cultured for 5 days. The integrity of the monolayers was checked by 
Evans blue-labeled bovine serum albumin (EBA, 67 kDa; 0.167 mg/mL EB, 10 mg/mL BSA) 
permeability marker molecule. The cells were treated with SNP, SNP-B or SNP-B-GSH diluted 
in culture medium at 150 µg/mL concentration in the upper, donor compartments (0.5 mL) for 
8 h. After incubation samples were collected from the lower or acceptor compartments (1.5 mL) 
and measured with a spectrofluorometer at 488 nm excitation and 605 nm emission wavelengths 
for the SNPs and at 584 nm excitation and 680 nm emission wavelengths for EBA to calculate 
the apparent permeability coefficients (Papp, cm/s).  
  
5 
 
3.5. Experiments with targeted vesicular nanoparticles  
3.5.1. Functionalization and characterization of niosomes 
Niosomes, the vesicular NPs used in our experiments, were made from non-ionic 
surfactants Span 60 (sorbitane-monostearate) and Solulan C24 (cholesteryl-poly-24-
oyxyethylene-ether), and cholesterol as shown on Fig. 3. 
Niosomes were functionalized with N-dodecyl-β-D-glucopyranose (GP), dodecanoyl-
alanine (A) or pegylated-GSH (GSH) to prepare targeted niosomes (N-GP, N-A, N-GSH) or 
dual-targeted NPs (N-A-GP, N-A-GSH, N-GP-GSH). The red fluorescent EBA was 
encapsulated in niosomes as a model cargo molecule. The NPs were characterized for particle 
size and zeta potential using dynamic light scattering. To examine the stability of particles the 
physico-chemical properties of niosome samples have been followed for 6 month. The amount 
of the encapsulated EBA in the NPs was determined by a spectrofluorometer. The niosomes 
were visualized by transmission and atomic force microscopy. 
3.5.2. Viability and cellular uptake measurements 
The kinetics of RBECs reaction to niosome treatment was monitored in real time by 
impedance measurement. To measure the cellular uptake of niosomes confluent monlayers of 
RBECs were incubated with single or dual-targeted niosomes (10 mg/mL concentration, 4 ºC 
or 37 ºC). To elucidate the uptake mechanisms of targeted niosomes cells were treated with 
sodium azide, a metabolic inhibitor (1 mg/mL) or with inhibitors of endocytosis, filipin (6 µM, 
15 min) or cytochalasin D (20 µM, 1 h). To study the role of the surface charge in the cellular 
uptake of NPs the surface glycocalyx of RBECs was digested with neuraminidase (1 U/mL, 
1h), or the cells were treated with TMA-DPH, a cationic lipid (54 µM, 30 min) before the uptake 
experiments. At the end of the uptake experiments the cells were washed, lysed and the 
fluorescent signal in the samples was detected by a spectrofluorometer.   
Figure 3. Preparation steps of niosomes: (1-2) dissolving non-ionic surfactants, cholesterol and transporter 
ligands in ethanol and chloroform, (3) lipid film formation by evaporation of solvents, (4) hydratation of dried 
lipid film with the solution containing cargo molecules followed by sonication, (5) high pressure extrusion, (6) 
ultracentrifugation. 
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3.5.3. Permeability measurements on the BBB co-culture model 
To determine the permeabilty of the cargo encapsulated in NPs across the BBB triple co-
culture model the cells were treated in the upper, donor compartment with single or dual-
targeted niosomes for 4 h. After incubation samples were collected from the lower, acceptor 
compartments and measured with a spectrofluorometer at 584 nm excitation and 663 nm 
emission wavelengths, then the Papp values of the EBA cargo were calculated. 
3.5.4. Membrane fluidity measurements on cells treated with niosomes 
To measure the plasma membrane fluidity, RBECs grown in culture dishes were treated 
with N and N-A-GSH samples for 4 h at 37°C in a CO2 incubator. Cells were labeled with 
TMA-DPH, a fluorescent lipid probe (0.2 µM, 5 min). Fluorescence anisotropy was measured 
on a T-format fluorescence spectrometer, excitation and emission wavelengths were 360 and 
430 nm, respectively. Anisotropy data were acquired in every second for 5 min, then benzyl 
alcohol (50 mM), a strong membrane fluidizer, was added and data were acquired for another 
5 min.  
3.5.5. In vivo experiments 
Ten-week old male CD1-Foxn1nu nude mice were used for in vivo imaging. The different 
niosomes (N, N-A, N-GP, N-A-GP), containing EBA as cargo, were injected intravenously. A 
time domain in vivo small animal fluorescence imager Optix™ was used to monitor the brain 
penetration of the red fluorescent EBA in real-time and over several time points in the same 
animal. The fluorescent signal was detected over the brain of living anesthetized mice in 0.5 
mm steps. For fluorescence detection, a time-correlated single-photon counting system 
(TCSPC-130) was used.  
3.5.6. Statistical analysis 
Data are presented as means ± SEM or SD. Values were compared using unpaired t-test, 
one-way or two-way analyses of variances (ANOVA) following Dunnett or Bonferroni multiple 
comparison posttests (GraphPadPrism 5.0). Changes were considered statistically significant at 
P < 0.05. All experiments were repeated at least two times and the number of parallel samples 
was 4-10. 
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4. RESULTS 
4.1. Expression of selected solute carrier genes coding nutrient transporters  
We verified the expression of genes for SLC transporters carrying glucose, alanine and 
biotin in freshly isolated rat brain microvessels, RBECs from triple culture BBB model and 
hCMEC/D3 cells (Fig. 4). Among the carriers of glucose, the expression level of the gene 
GLUT1, coding the predominant glucose transporter at the BBB, was the highest. From the 
tested neutral amino acid transporters the mRNA level of SNAT2 was the highest in all models. 
The expression levels of the SMVT gene were similar in the BBB model and the hCMEC/D3 
cells. From the tested ten genes only in three cases, for GLUT5, SNAT1 and SNAT5 were 
transcript levels lower in the BBB model than in brain microvessels and/or hCMEC/D3 cells 
(Fig. 4).  
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Figure 4. Expression of genes encoding solute carriers for glucose, alanine and biotin in isolated rat brain 
microvessels, primary rat brain endothelial cells co-cultured with rat pericytes and astrocytes, and hCMEC/D3 
human brain endothelial cell line. 
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4.2. Results with solid nanoparticles 
4.2.1. Characterization of the non-targeted and targeted solid nanoparticles 
The fluorescent SNPs were labeled with biotin and glutathione targeting ligands (Fig. 5). 
The size of SNPs varied between 93-120 nm. All SNP groups had low polydispersity index, 
indicating a relatively narrow size distribution. The average zeta potential for both targeted 
particles was very similar (−23 mV). The charge of the non-labeled SNP was less negative. The 
particles had mostly spherical shapes, but some SNPs were elongated. No aggregation was 
visible. 
 
4.2.2. Viability measurement and cellular uptake of solid nanoparticles 
Incubation of the human brain endothelial cell monolayers with SNP and SNP-B in the 
10-1000 µg/mL concentration range for 24 h had no effect on cell viability assessed by MTT 
dye conversion test. For further experiments we selected the 150 µg/mL concentration for all 
three SNPs, which can be considered as non-toxic. 
The uptake of SNPs in hCMEC/D3 was tested at two time points (4 and 8 h). After 8 h 
incubation the uptake of all tested nanoparticles was significantly higher compared to the 4 h 
group. Importantly, the uptake of the biotin- and glutathione-targeted SNPs was significantly 
increased; it was two times higher than the uptake of the non-targeted particle (Fig. 6). 
Figure 5. Schematic drawing of non-targeted (SNP), biotin- (SNP-B) and glutathione-labeled (SNP-B-GSH) solid 
nanoparticles.  
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Figure 6. The uptake of non-targeted (SNP), biotin-labeled (SNP-B) and glutathione-labeled (SNP-B-GSH) solid 
nanoparticles in brain endothelial cells after 4 or 8 h incubation. The concentration of SNPs was 150 µg/mL in 
all groups. Values presented are means ± SEM. Statistical analysis: two-way ANOVA followed by Bonferroni 
posttest, where **P < 0.01; ***P < 0.001, compared to SNP treated group, ##P < 0.01; ###P < 0.001, compared 
to the 4 h incubation group; n = 4–6. 
 
4.2.3. Penetration of solid nanoparticles across brain endothelial monolayers  
All SNPs crossed the brain endothelial layers in the permeability tests but at different 
extent (Fig. 7). After 8 h incubation the Papp of biotin targeted SNPs was 2.8 fold higher than 
that of the non-targeted SNPs. The penetration of the GSH targeted nanoparticles was the 
highest: a significant, 5.8 fold increase was measured as compared to the unlabeled SNP group.  
 
Figure 7. Permeability assay for targeted and non-targeted SNPs (150 µg/mL, 8 h) across hCMEC/D3 cell 
monolayers. Values presented are means ± SEM. Statistical analysis: one-way ANOVA followed by Bonferroni 
posttest. *P < 0.05, ***P < 0.001, compared to non-labeled SNP treated group; ##P < 0.01, compared to biotin-
labeled SNP treated group, n = 6. 
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4.2. Results with niosomes 
4.2.1. Characterization of non-targeted and targeted niosomes 
Seven types of niosomes (non-targeted, N), single ligand targeted (N-GP, N-A, N-GSH), 
and dual-ligand targeted (N-A-GSH, N-A-GP, N-GP-GSH) were prepared with the fluorescent 
EBA cargo (Fig. 8).  
 
Figure 8. Schematic drawing of non-targeted (N), single ligand targeted (N-A: alanine, N-GP: glucopyranose, N-
GSH: glutathione) and dual-targeted niosomes (N-A-GP: glucose-alanine, N-A-GSH: alanine-glutathione, N-GP-
GSH: glucose-glutathione). EBA: Evans blue-albumin complex. 
The average diameter of niosomes varied between 92 and 107 nm. All groups had low 
polydispersity index, indicating a narrow size distribution. The zeta potentials of niosomes were 
between −3 and −4 mV, except those decorated with GSH ligand (N-GSH, N-A-GSH, N-GP-
GSH), which had a more negative surface charge, around −7mV. The encapsulation eﬃciency 
of the cargo EBA was in the range of 4.6–10.4%. The amount of the encapsulated large 
hydrophilic biomolecule EBA was between 0.5 and 1.1 mg/100 mg nanoparticle total weight.  
The morphology of the NPs was spherical as observed by transmission electron 
microscopy (Fig. 9A) and atomic force microscopy (Fig. 9B). No aggregation was visible.  
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Figure 9. (A) Transmission electron microscopy image of niosomes, bar: 500 nm. (B) Atomic force microscopy 
image of niosomes. 
The stability of non-targeted niosomes loaded with EBA was followed for six months. 
The size of niosomes changed from 92.8 ± 1.8 nm to 119.5 ± 1.9 nm during this period. At 6 
months the physico-chemical properties have changed minimally. Based on these data the 
niosome preparations can be considered as stable regarding size, encapsulated cargo and 
aggregation for at least 6 months.  
4.2.2. Viability and cellular uptake measurements 
Incubation of RBECs with non-targeted or targeted niosomes in the 0.3–10 mg/mL 
concentration range for 4h did not decrease the impedance of cell layers reﬂecting good cell 
viability. For further experiments we selected the 10 mg/mL concentration, which can be 
considered as a safe concentration for all niosome groups. The uptake of the large hydrophilic 
free EBA was very low in brain endothelial cells, only 1.5% of the EBA uptake measured in 
cells treated with non-targeted niosome (N) containing the cargo (Fig.10).  
 
Figure 10. The uptake of EBA in brain endothelial cells treated with non-targeted (N), single- (N-A, N-GP, N-
GSH) and dual-targeted (N-A-GP, N-A-GSH, N-GP-GSH) niosomes (4 h). Values presented are means ± SEM. 
Statistical analysis: ANOVA followed by Dunnett's posttest, where ***P < 0.001, compared to non-targeted N 
group; n=10. 
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As compared to non-targeted niosomes, the uptake of EBA in RBECs treated with 
nanovesicles decorated with alanine, glucopyranose or glutathione was higher. The presence of 
dual-ligands increased the cellular concentration of EBA in brain endothelial cells in the case 
of N-A-GP and N-A-GSH groups, but not in the N-GP-GSH group (Fig. 10).  
 
4.2.3. Penetration of the cargo of targeted niosomes across BBB co-culture model 
The permeability of the BBB model for EBA was also very low reﬂecting a tight barrier 
(Fig. 11). The encapsulation of EBA in non-targeted niosomes (N) increased the permeability 
of the cargo through RBECs. Labeling the particles with single ligands resulted in further 
increase in the penetration of EBA across the BBB model. The amount of EBA cargo that 
crossed brain endothelial cells was increased 17-fold in case of the N-A-GSH group and 14-
fold in the N-A-GP group as compared to the EBA group (Fig. 11). The combination of GP-
GSH ligands was not eﬃcient to elevate EBA penetration across the BBB model. Based on the 
results, the N-A, N-GSH and N-A-GSH groups were selected for further in vitro experiments. 
 
Figure 11. Permeability of albumin cargo across the BBB culture model after treatment with diﬀerent niosomes 
(10 mg/mL, 4h). Values presented are means ± SEM. Statistical analysis: ANOVA, Dunnett's posttest. **P < 0.01, 
compared to non-targeted N group; n=10.  
 
4.2.6. Cellular uptake: temperature dependence and metabolic inhibition 
At 37 °C the EBA uptake was signiﬁcantly higher in all targeted nanovesicle groups 
compared to the non-targeted group (Fig. 12). Decreased EBA uptake was seen in RBECs at 
4 °C and after treatment of the cells with metabolic inhibitor sodium azide in all targeted groups. 
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Figure 12. The eﬀect of temperature and metabolic inhibitor sodium azide (0.1%) on the uptake of EBA cargo in 
brain endothelial cells after 4h incubation with non-targeted (N), alanine-targeted (N-A), glutathione-targeted (N-
GSH) and alanine-glutathione-targeted (N-A-GSH) niosomes. Values presented are means ± SEM. Statistical 
analysis: two-way ANOVA, Bonferroni posttest. *P < 0.5; **P < 0.01; ***P < 0.001, compared to ﬁrst column 
of each groups, ###P < 0.001, compared to N treated group; n=4–6. 
 
4.2.7. Cellular uptake: inhibition of endocytosis 
Two inhibitors of endocytosis were used to further elucidate the mechanism of cellular 
uptake of EBA in cells treated with dual-targeted N-A-GSH particles (Fig. 13). Filipin, which 
inhibits lipid raft/caveolae-mediated endocytosis (Fig. 13B), slightly, but statistically 
signiﬁcantly decreased the uptake of cargo in RBECs (Fig. 13A). Cytochalasin-D, a commonly 
used inhibitor of endocytosis which blocks F-actin depolymerization (Fig. 13B), also induced 
a partial, but signiﬁcant inhibition of EBA uptake (Fig. 13A). 
Figure 13. (A) Inhibition of the uptake of EBA cargo with ﬁlipin (6 μM) or cytochalasin D (20 μM) in rat brain 
endothelial cells after 4 h incubation with alanine-glutathione dual-targeted niosomes (N-A-GSH). Values 
presented are means ± SEM. Statistical analysis: ANOVA followed by Dunnett's posttest. *P < 0.5; ***P < 0.001, 
compared to the control group; n=6. (B) Schematic drawing of the effect of cytochalasin D and filipin. 
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4.2.8. Cellular uptake: modiﬁcation of cell surface charge 
We modified the surface charge of cultured brain endothelial cells by digestion of the 
surface glycocalyx with neuraminidase enzyme and treatment with a cationic lipid, TMA-DPH. 
Surface charge alterations in RBECs did not aﬀect the cellular uptake of EBA after treatment 
with non-targeted NPs as compared to the control, untreated group (Fig. 14A).  
 
Figure 14. (A) The eﬀect of neuraminidase (1 U/mL) and TMA-DPH (54 µM) on the uptake of EBA cargo in brain 
endothelial cells incubated with non-targeted (N) and alanine-glutathione dual-targeted niosomes (N-A-GSH). 
Statistical analysis: two-way ANOVA, Bonferroni posttest. **P < 0.01 compared to ﬁrst column of each groups; 
###P < 0.001, compared to N treated groups; n=6. (B) Schematic drawing on the effect of TMA-DPH and 
neuraminidase on the surface charge of RBEC. 
 
In contrast, both modiﬁcations increased the uptake of EBA in brain endothelial cells 
after incubation with N-A-GSH niosomes (Fig. 14). The uptake of EBA was increased by 16%, 
after treatment of RBECs with neuraminidase and by 19% after incubation with TMA-DPH, as 
compared to untreated cells in the N-A-GSH nanoparticle group.  
 
4.2.9. Interaction of nanovesicles with brain endothelial cells: plasma membrane ﬂuidity 
The ﬂuorescence anisotropy measured in a single cell suspension of living brain 
endothelial cells was signiﬁcantly decreased after 4h treatment with N and N-A-GSH 
nanovesicles (Fig. 15A) indicating increased cell membrane ﬂuidity and a fusion process 
(Fig. 15B). The membrane ﬂuidizer benzyl alcohol (30 mM) quickly and greatly reduced the 
TMA-DPH ﬂuorescence anisotropy after 3 min compared to the control and niosome treated 
groups indicating maximal plasma membrane ﬂuidity. 
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Figure 15. (A) The eﬀect of non-targeted (N) and alanine-glutathione dual-targeted niosomes (N-A-GSH), and 
benzyl alcohol (30 mM) on plasma membrane ﬂuidity measured by ﬂuorescence anisotropy of living brain 
endothelial cells in suspension. Values presented are means ± SEM. Statistical analysis: two-way ANOVA, 
Bonferroni posttest. ***P < 0.001, all groups were compared to non-treated control (C); ###P < 0.001, compared 
to ﬁrst column of each groups, n=3. (B) Schematic drawing on the fusion of a niosome with cellular plasma 
membrane. 
4.2.10. Imaging of EBA cargo in mice after intravenous injection of targeted niosomes 
The brain penetration of the red ﬂuorescent EBA was measured by in vivo imaging in 
nude mice. In animals which were injected with free EBA there was no signiﬁcant elevation in 
the signal intentsity in the brain area during the experiment (Fig. 16). Encapsulation of EBA in 
non-targeted niosomes resulted in enhanced brain ﬂuorescence intensity. The ﬂuorescent signal 
in the brain area was further increased in the single ligand targeted N-A and N-GP groups, while 
in the dual-ligand targeted N-A-GP group it was the highest, as compared to all groups at all 
time points (Fig. 16). The diﬀerences between targeted, dual-ligand targeted and non-targeted 
niosomes were still visible at 24 h. 
 
Figure 16. Fluorescence intensity of EBA in the brain regions of mice after injection of free EBA or EBA 
encapsulated in non-targeted (N), single- (N-A, N-GP) or dual-targeted (N-A-GP) niosomes measured by optical 
imaging. Values presented are means ± SD. Statistical analysis: two-way ANOVA, Bonferroni posttest.* P < 0.5; 
**P < 0.01; ***P < 0.001, as compared to the EBA-treated group within each time point; a: as compared to the 
10 min, b: as compared to the 30 min, c: as compared to the 3h, d: as compared to the 6 h time points within each 
group, n=3–4.   
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5. SUMMARY 
NPs for drug targeting across the BBB are promising candidates to increase the brain 
penetration of biopharmacons for treating CNS diseases. Effective targeting of NPs can only be 
achieved by exploiting the BBB specific physiological transport pathways. Despite the 
abundance of carrier mediated transporters at the BBB this pathway is still underresearched for 
drug delivery.  
Solute carriers functioning as nutrient transporters are expressed at high levels in brain 
endothelial cells and show a specific pattern at the BBB. Our hypothesis was, that targeting 
SLCs expressed at the BBB can enhance nanoparticle uptake and permeability across brain 
endothelial cells, and using ligands for two different SLCs at the same time could further 
increase nanoparticle penetration. The aim of our studies was to identify and test SLC 
transporter ligands and glutathione as single or dual BBB targeting molecules for solid and 
vesicular NPs.  
In our first study we tested biotin-labeled solid NPs and compared them to glutathione-
labeled NPs on an in vitro BBB model. Fluorescent polystyrene NPs were derivatized and 
investigated on human brain endothelial cells. We verified that hCMEC/D3 cells express 
mRNA for sodium-dependent multivitamin transporter (SMVT/SLC5A6) responsible for the 
BBB transport of biotin. Biotin as a ligand increased the uptake and the transfer of NPs across 
brain endothelial cells. Glutathione could further increase NP permeability across the BBB 
model, supporting its use as a brain targeting vector. 
In the second series of experiments vesicular NPs were investigated. High mRNA 
expression levels for hexose and neutral amino acid transporting SLCs were found in isolated 
rat brain microvessels and a rat primary cell based co-culture BBB model. Niosomes, 
nanovesicles prepared from non-ionic surfactants, were decorated with glutathione and SLC 
ligands glucopyranose and alanine, and loaded with Evans blue-albumin complex as a large 
biomolecule model cargo. The presence of targeting ligands on niosomes, especially dual 
labeling, increased the uptake of the cargo molecule in cultured brain endothelial cells. This 
cellular uptake was temperature dependent and decreased following application of a metabolic 
inhibitor, sodium azide, and endocytosis blockers filipin and cytochalasin D. Turning the 
negative surface charge of brain endothelial cells more positive with a cationic lipid or digesting 
the glycocalyx with neuraminidase elevated the uptake of the cargo encapsulated in targeted 
nanocarriers. Niosomes increased plasma membrane fluidity, suggesting the fusion of 
nanovesicles with the endothelial cell membranes. Targeting ligands elevated the permeability 
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of the cargo across the BBB in the culture model and in mice, and dual-ligand decoration of 
niosomes was more effective than single ligand labeling. As a conclusion, our data indicate that 
ligands of multiple SLC transporters can be exploited for BBB targeting of NPs.  
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